An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer (FAR-122)
This study has been terminated.
(study did not meet pre-specified criteria for continuation following interim futility analysis)
First Posted: August 20, 2008
Last Update Posted: March 30, 2017
Information provided by (Responsible Party):